sv1za
As filed
with the Securities and Exchange Commission on July 27,
2010
Registration
No. 333-166825
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
Amendment No. 4
to
Form S-1
REGISTRATION
STATEMENT
UNDER
THE SECURITIES ACT OF
1933
NuPathe
Inc.
(Exact name of registrant as
specified in its charter)
|
|
|
|
|
Delaware
(State or other jurisdiction
of
incorporation or organization)
|
|
2834
(Primary Standard
Industrial
Classification Code Number)
|
|
20-2218246
(I.R.S. Employer
Identification Number)
|
227 Washington Street, Suite 200
Conshohocken, Pennsylvania 19428
(484) 567-0130
(Address, including zip code and
telephone number, including area code, of registrants
principal executive offices)
Jane H. Hollingsworth
Chief Executive Officer
NuPathe Inc.
227 Washington Street, Suite 200
Conshohocken, Pennsylvania 19428
(484) 567-0130
(Name, address, including zip
code and telephone number, including area code, of agent for
service)
Copies
to:
|
|
|
|
|
Michael N. Peterson, Esq.
James W. McKenzie, Jr., Esq.
Morgan, Lewis & Bockius LLP
1701 Market Street
Philadelphia, Pennsylvania 19103
(215) 963-5000
|
|
Suzanne M. Hanlon, Esq.
V.P. Administration, General Counsel, Secretary
NuPathe Inc.
227 Washington Street, Suite 200
Conshohocken, Pennsylvania 19428
(484) 567-0130
|
|
David E. Redlick, Esq.
Brian A. Johnson, Esq.
Wilmer Cutler Pickering Hale and Dorr LLP
399 Park Avenue
New York, New York 10022
(212) 230-8800
|
Approximate date of commencement of proposed sale to the
public: As soon as practicable after the
effective date of this registration statement.
If any of the securities being registered on this form are to be
offered on a delayed or continuous basis pursuant to
Rule 415 under the Securities Act of 1933, check the
following
box. o
If this Form is filed to register additional securities for an
offering pursuant to Rule 462(b) under the Securities Act,
check the following box and list the Securities Act registration
statement number of the earlier effective registration statement
for the same
offering. o
If this Form is a post-effective amendment filed pursuant to
Rule 462(c) under the Securities Act, check the following
box and list the Securities Act registration statement number of
the earlier effective registration statement for the same
offering. o
If this Form is a post-effective amendment filed pursuant to
Rule 462(d) under the Securities Act, check the following
box and list the Securities Act registration statement number of
the earlier effective registration statement for the same
offering. o
Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated
filer, or a smaller reporting company. See the definitions of
large accelerated filer, accelerated
filer and smaller reporting company in
Rule 12b-2
of the Exchange Act. (Check one):
|
|
|
|
Large
accelerated
filer o
|
Accelerated
filer o
|
Non-accelerated
filer þ
|
Smaller reporting
company o
|
(Do not check if a smaller
reporting company)
The Registrant hereby amends this Registration Statement on
such date or dates as may be necessary to delay its effective
date until the Registrant shall file a further amendment which
specifically states that this Registration Statement shall
thereafter become effective in accordance with Section 8(a)
of the Securities Act of 1933 or until the Registration
Statement shall become effective on such date as the Commission,
acting pursuant to said Section 8(a), may determine.
EXPLANATORY
NOTE
This Amendment No. 4 to the Registrants Registration
Statement on
Form S-1
(File
No. 333-166825)
is being filed solely for the purpose of revising Part II,
Item 13, and filing updated Exhibits 10.2, 10.4, 10.5
and 10.11 in order to respond to comments received from the
Securities and Exchange Commission to the Registrants
Application for Confidential Treatment. No changes or additions
are being made hereby to the prospectus that forms a part of the
Registration Statement. Accordingly, the prospectus is being
omitted from this filing.
PART II
INFORMATION
NOT REQUIRED IN PROSPECTUS
|
|
Item 13.
|
Other
expenses of issuance and distribution.
|
The following table sets forth all costs and expenses, other
than underwriting discounts and commissions, in connection with
the sale of the common stock being registered, all of which will
be paid by us. All amounts shown are estimates except for the
Securities Exchange Commission, or SEC, registration fee, the
Financial Industry Regulatory Authority, or FINRA, filing fee
and the listing fee for The NASDAQ Global Market.
|
|
|
|
|
|
|
Amount Paid
|
|
|
|
or to be Paid
|
|
|
SEC registration fee
|
|
$
|
6,560
|
|
FINRA filing fee
|
|
|
9,700
|
|
The NASDAQ Global Market listing fee
|
|
|
125,000
|
|
Blue sky qualification fees and expenses
|
|
|
15,000
|
|
Printing expenses
|
|
|
225,000
|
|
Legal fees and expenses
|
|
|
1,333,000
|
|
Accounting fees and expenses
|
|
|
650,000
|
|
Transfer agent and registrar fees and expenses
|
|
|
1,500
|
|
Director and officer liability insurance policy premium
|
|
|
350,000
|
|
Financial advisory fee
|
|
|
375,000
|
|
Miscellaneous expenses
|
|
|
209,240
|
|
|
|
|
|
|
Total Expenses
|
|
$
|
3,300,000
|
|
|
|
|
|
|
|
|
Item 14.
|
Indemnification
of directors and officers.
|
Section 102(b)(7) of the DGCL provides that a Delaware
corporation, in its certificate of incorporation, may limit the
personal liability of a director to the corporation or its
stockholders for monetary damages for breach of fiduciary duties
as a director, except for liability for any:
|
|
|
|
|
Transaction from which the director derived an improper personal
benefit;
|
|
|
|
Act or omission not in good faith or that involved intentional
misconduct or a knowing violation of law;
|
|
|
|
Unlawful payment of dividends or redemption of shares; or
|
|
|
|
Breach of the directors duty of loyalty to the corporation
or its stockholders.
|
Section 145(a) of the DGCL provides, in general, that a
Delaware corporation may indemnify any person who was or is a
party, or is threatened to be made a party, to any threatened,
pending or completed action, suit or proceeding, whether civil,
criminal, administrative or investigative (other than an action
by or in the right of the corporation) because that person is or
was a director, officer, employee or agent of the corporation,
or is or was serving at the request of the corporation as a
director, officer, employee or agent of another corporation or
other enterprise. The indemnity may include against expenses
(including attorneys fees), judgments, fines and amounts
paid in settlement actually and reasonably incurred by the
person in connection with such action, so long as the person
acted in good faith and in a manner he or she reasonably
believed was in or not opposed to the corporations best
interests of the corporation, and, with respect to any criminal
action or proceeding, had no reasonable cause to believe his or
her conduct was unlawful.
Section 145(b) of the DGCL provides, in general, that a
Delaware corporation may indemnify any person who was or is a
party, or is threatened to be made a party, to any threatened,
pending or completed action or suit by or in the right of the
corporation to obtain a judgment in its favor because the person
is or was a director, officer, employee or agent of the
corporation, or is or was serving at the request of the
corporation as a director, officer, employee or agent of another
corporation or other enterprise. The indemnity may include
II-1
expenses (including attorneys fees) actually and
reasonably incurred by the person in connection with the defense
or settlement of such action, so long as the person acted in
good faith and in a manner the person reasonably believed was in
or not opposed to the corporations best interests, except
that no indemnification shall be permitted without judicial
approval if a court has determined that the person is to be
liable to the corporation with respect to such claim. If a
present or former director or officer has been successful in
defense of any action referred to above, the corporation must
indemnify such officer or director against the expenses
(including attorneys fees) he or she actually and
reasonably incurred in connection with such action.
Section 145(g) of the DGCL provides, in general, that a
corporation may purchase and maintain insurance on behalf of any
person who is or was a director, officer, employee or agent of
the corporation, or is or was serving at the request of the
corporation as a director, officer, employee or agent of another
corporation or other enterprise against any liability asserted
against and incurred by such person, in any such capacity, or
arising out of his or her status as such, whether or not the
corporation could indemnify the person against such liability
under Section 145 of the DGCL.
Our restated certificate of incorporation, which will become
effective upon the closing of this offering, limits the
liability of our directors to the fullest extent permitted
under the DGCL. Our bylaws, which will become effective upon the
closing of this offering, and our Investor Rights Agreement,
each provide for the indemnification of our directors and
officers to the fullest extent permitted under the DGCL.
In addition to the indemnification provisions provided for in
our charter documents, we have entered into separate
indemnification agreements with our directors. These
indemnification agreements provide, among other things, that we
will indemnify our directors for certain expenses, including
damages, judgments, fines, penalties, settlements and costs and
attorneys fees and disbursements, incurred by a director
in any claim, action or proceeding arising in his or her
capacity as a director of our company or in connection with
service at our request for another corporation or entity. The
indemnification agreements also provide for procedures that will
apply in the event that a director makes a claim for
indemnification.
At present, there is no pending litigation or proceeding
involving any of our directors or officers as to which
indemnification is required or permitted, and we are not aware
of any threatened litigation or proceeding that may result in a
claim for indemnification.
We maintain a general liability insurance policy which covers
certain liabilities of our directors and officers arising out of
claims based on acts or omissions in their capacities as
directors or officers.
We intend to purchase and maintain an insurance policy
which covers certain liabilities of our officers and directors
arising out of claims based on acts or omissions in their
capacities as officers and directors, including liabilities
arising under the Securities Act, the Exchange Act or otherwise.
We have entered into an underwriting agreement, which provides
for indemnification by the underwriters of us, our officers and
directors, for certain liabilities, including liabilities
arising under the Securities Act.
|
|
Item 15.
|
Recent
sales of unregistered securities.
|
The following list sets forth information regarding all
securities sold by us in the three years preceding the filing of
this registration statement:
Preferred
Stock Financings
(a) In August 2006, we entered into a Series A
Preferred Stock Purchase Agreement pursuant to which we issued
and sold an aggregate of 19,610,677 shares of Series A
preferred stock in four separate closings from August 2006
through April 2008, at a purchase price of $0.93 per share, for
aggregate consideration of $15,000,000 in cash and $2,590,343 in
aggregate principal and interest due under convertible
promissory notes held by existing investors, which pursuant to
the terms of such notes was converted into shares of
Series A preferred stock.
(b) In July 2008, we entered into a Series B Preferred
Stock Purchase Agreement pursuant to which we issued and sold an
aggregate of 33,485,663 shares of Series B preferred
stock in three separate closings from
II-2
July 2008 through August 2009, at a purchase price of $0.93 per
share, for aggregate consideration of $29,184,643 in cash and
$1,957,023 in aggregate principal and interest due under
convertible promissory notes held by existing investors, which
pursuant to the terms of such notes was converted into shares of
Series B preferred stock. In addition,
2,688,171 shares of Series A preferred stock that were
acquired in a prior financing by certain persons participating
in the Series B financing were exchanged for an equal number of
shares of Series B preferred stock.
Convertible
Note Financings and Warrant Issuances
(c) In July 2009, we received gross proceeds of $1,934,183
from the sale of convertible promissory notes in a private
placement to certain of our existing investors. In
August 2009, the convertible promissory notes converted
into shares of Series B preferred stock pursuant to the
terms of such notes. Upon such conversion, warrants to purchase
an aggregate of 736,514 shares of Series B preferred
stock were issued to the holders of such notes, which, upon the
closing of this offering, will become warrants to purchase
91,890 shares of common stock in accordance with their
terms.
(d) In April 2010, we received gross proceeds of
$10,062,500 from the sale of the convertible promissory notes in
a private placement to certain of our existing investors. The
convertible promissory notes accrue interest at a rate equal to
8% per year, compounding monthly, and have a maturity date of
December 31, 2010, unless converted prior thereto. The
convertible promissory notes are automatically convertible into
common stock upon the closing of this offering at a conversion
price equal to 80% of the price to the public in this offering.
(e) In May 2010, we entered into a $5.0 million
secured term loan facility. In connection with such loan we
issued the lenders warrants to purchase 255,376 shares of
Series B preferred stock at an exercise price of $0.93 per
share. Upon the closing of this offering, in accordance with
their terms, the warrants will automatically become exercisable
for 31,861 shares of common stock at an exercise price of
$7.45 per share of common stock.
Stock
Option Grants
(f) From May 14, 2007 through June 30, 2010, we
granted stock options under our 2005 Equity Compensation Plan to
purchase an aggregate of 868,478 shares of common stock
with a weighted average exercise price of $1.92 per share, to
certain of our employees, consultants and directors. In
addition, upon the effective date of the registration statement
for this offering, we will grant options to purchase
345,350 shares of common stock at an exercise price equal
to the initial public offering price.
Securities
Act Exemptions
We deemed the offers, sales and issuances of the securities
described in paragraphs (a) through (e) and to the
extent applicable a portion of the stock options described in
paragraph (f) granted to executive officers to be exempt from
registration under the Securities Act in reliance on
Section 4(2) of the Securities Act, including
Regulation D and Rule 506 promulgated thereunder,
relative to transactions by an issuer not involving a public
offering. All purchasers of securities in transactions exempt
from registration pursuant to Regulation D represented to
us that they were accredited investors and were acquiring the
shares for investment purposes only and not with a view to, or
for sale in connection with, any distribution thereof and that
they could bear the risks of the investment and could hold the
securities for an indefinite period of time. The purchasers
received written disclosures that the securities had not been
registered under the Securities Act and that any resale must be
made pursuant to a registration statement or an available
exemption from such registration.
We deemed the grants of stock options described in paragraph
(f), except to the extent described above as exempt pursuant to
Section 4(2) of the Securities Act, to be exempt from
registration under the Securities Act in reliance on
Rule 701 of the Securities Act as offers and sales of
securities under compensatory benefit plans and contracts
relating to compensation in compliance with Rule 701. Each
of the recipients of securities in any transaction exempt from
registration either received or had adequate access, through
employment, business or other relationships, to information
about us.
II-3
All certificates representing the securities issued in the
transactions described in this Item 15 included appropriate
legends setting forth that the securities had not been offered
or sold pursuant to a registration statement and describing the
applicable restrictions on transfer of the securities. There
were no underwriters employed in connection with any of the
transactions set forth in this Item 15.
|
|
Item 16.
|
Exhibits
and financial statement schedules.
|
(a) Exhibits.
The exhibits to the registration statement are listed in the
Exhibit Index attached hereto and incorporated by reference
herein.
(b) Financial Statements Schedules.
No financial statement schedules are provided because the
information called for is not required or is shown either in the
financial statements or the notes thereto.
(a) The undersigned registrant hereby undertakes to provide
to the underwriter at the closing specified in the underwriting
agreement, certificates in such denominations and registered in
such names as required by the underwriter to permit prompt
delivery to each purchaser.
(b) Insofar as indemnification for liabilities arising
under the Securities Act may be permitted to directors, officers
and controlling persons of the registrant pursuant to the
foregoing provisions or otherwise, the registrant has been
advised that in the opinion of the SEC such indemnification is
against public policy as expressed in the Act and is, therefore,
unenforceable. In the event that a claim for indemnification
against such liabilities (other than the payment by the
registrant of expenses incurred or paid by a director, officer
or controlling person of the registrant in the successful
defense of any action, suit or proceeding) is asserted by such
director, officer or controlling person in connection with the
securities being registered, the registrant will, unless in the
opinion of its counsel the matter has been settled by
controlling precedent, submit to a court of appropriate
jurisdiction the question whether such indemnification by it is
against public policy as expressed in the Securities Act and
will be governed by the final adjudication of such issue.
(c) The undersigned registrant hereby undertakes that:
1) For purposes of determining any liability under the
Securities Act, the information omitted from the form of
prospectus filed as part of this registration statement in
reliance upon Rule 430A and contained in a form of
prospectus filed by the registrant pursuant to Rule 424(b)
(1) or (4) or 497(h) under the Securities Act shall be
deemed to be part of this registration statement as of the time
it was declared effective.
2) For the purpose of determining any liability under the
Securities Act, each post-effective amendment that contains a
form of prospectus shall be deemed to be a new registration
statement relating to the securities offered therein, and the
offering of such securities at that time shall be deemed to be
the initial bona fide offering thereof.
II-4
SIGNATURES
Pursuant to the requirements of the Securities Act, the
Registrant has duly caused this Amendment No. 4 to the
Registration Statement to be signed on its behalf by the
undersigned, thereunto duly authorized, in the city of
Conshohocken, Commonwealth of Pennsylvania, on the
27th day
of July, 2010.
NUPATHE INC.
|
|
|
|
By:
|
/s/ Jane
H. Hollingsworth
Jane
H. Hollingsworth
Chief Executive Officer
|
Pursuant to the requirements of the Securities Act of 1933, as
amended, this Amendment No. 4 to the Registration Statement
has been signed by the following persons in the capacities and
on the dates indicated.
|
|
|
|
|
|
|
Signature
|
|
Title
|
|
Date
|
|
/s/ Jane
H. Hollingsworth
Jane
H. Hollingsworth
|
|
Chief Executive Officer and Director (Principal Executive
Officer)
|
|
July 27, 2010
|
/s/ Keith
A. Goldan
Keith
A. Goldan
|
|
Chief Financial Officer
(Principal Financial and Accounting Officer)
|
|
July 27, 2010
|
*
Wayne
P. Yetter
|
|
Chairman of the Board
|
|
July 27, 2010
|
*
Michael
Cola
|
|
Director
|
|
July 27, 2010
|
*
Jeanne
Cunicelli
|
|
Director
|
|
July 27, 2010
|
*
Michael
C. Diem, M.D.
|
|
Director
|
|
July 27, 2010
|
*
Richard
S. Kollender
|
|
Director
|
|
July 27, 2010
|
*
Gary
J. Kurtzman, M.D.
|
|
Director
|
|
July 27, 2010
|
*
Robert
P. Roche, Jr.
|
|
Director
|
|
July 27, 2010
|
* Jane H. Hollingsworth, by signing her name hereto,
does hereby sign this document on behalf of each of the
above-named
directors of the registrant pursuant to powers of attorney duly
executed by such persons.
|
|
|
|
|
By: /s/ Jane
H. Hollingsworth
Jane
H. Hollingsworth
Attorney-in-Fact
|
|
|
|
|
II-5
Exhibit Index
|
|
|
|
|
Exhibit
|
|
|
Number
|
|
Description of Document
|
|
|
1
|
.1
|
|
Form of Underwriting Agreement
|
|
3
|
.1
|
|
Third Amended and Restated Certificate of Incorporation of
NuPathe Inc., as amended August 20, 2009, April 9,
2010, May 13, 2010 and July 20, 2010
|
|
3
|
.2
|
|
Form of Restated Certificate of Incorporation of NuPathe Inc.,
to be in effect upon the closing of this offering
|
|
3
|
.3
|
|
Bylaws of NuPathe Inc.
|
|
3
|
.4
|
|
Form of Bylaws of NuPathe Inc., to be in effect upon the closing
of this offering
|
|
4
|
.1
|
|
Amended and Restated Investor Rights Agreement, dated as of
July 8, 2008, as amended
|
|
4
|
.2
|
|
Preferred Stock Warrant, dated as of March 29, 2007, as
amended, issued to Oxford Finance Corp.
|
|
4
|
.3
|
|
Form Warrant to Purchase Shares of Series B Preferred
Stock, as amended
|
|
4
|
.4
|
|
Series B Preferred Stock Warrant, dated May 13, 2010,
issued to MidCap Funding III, LLC
|
|
4
|
.5
|
|
Series B Preferred Stock Warrant, dated May 13, 2010,
issued to Silicon Valley Bank
|
|
5
|
.1
|
|
Opinion of Morgan, Lewis & Bockius LLP
|
|
10
|
.1#
|
|
Patent License Agreement, effective as of July 1, 2006, as
amended, between NuPathe Inc. and The Trustees of the University
of Pennsylvania
|
|
10
|
.2#
|
|
Development and License Agreement, dated September 14,
2007, as amended, between NuPathe Inc. and LTS Lohmann
Therapie-Systeme AG
|
|
10
|
.3
|
|
Asset Purchase and License Agreement, dated July 8, 2008,
between NuPathe Inc. and Travanti Pharma Inc.
|
|
10
|
.4#
|
|
Feasibility Evaluation Agreement, dated March 19, 2007, as
amended, between NuPathe Inc. and SurModics Pharmaceuticals,
Inc. (f/k/a Brookwood Pharmaceuticals, Inc.)
|
|
10
|
.5#
|
|
License Agreement, dated September 23, 2009, between
NuPathe Inc. and SurModics Pharmaceuticals, Inc. (f/k/a
Brookwood Pharmaceuticals, Inc.)
|
|
10
|
.6
|
|
Secured Subordinated Convertible Note and Warrant Purchase
Agreement, dated April 9, 2010, between NuPathe Inc. and
the Purchasers named therein
|
|
10
|
.7
|
|
Loan and Security Agreement, effective as of May 13, 2010,
by and among MidCap Funding III, LLC, Silicon Valley Bank and
NuPathe Inc.
|
|
10
|
.8
|
|
Secured Promissory Note, dated May 13, 2010, made by
NuPathe Inc. in favor of MidCap Funding III, LLC
|
|
10
|
.9
|
|
Secured Promissory Note, dated May 13, 2010, made by
NuPathe Inc. in favor of Silicon Valley Bank
|
|
10
|
.10
|
|
Office Space Lease, dated January 10, 2008, between NuPathe
Inc. and Washington Street Associates II, L.P.
|
|
10
|
.11#
|
|
Equipment Funding Agreement, dated June 1, 2010, between
NuPathe Inc. and LTS Lohmann Therapie-Systeme AG
|
|
10
|
.12
|
|
Amended and Restated 2005 Equity Compensation Plan, as amended,
including forms of Incentive Stock Option Grant, Nonqualified
Stock Option Grant and Restricted Stock Grant Agreement
thereunder
|
|
10
|
.13
|
|
2010 Omnibus Incentive Compensation Plan, including forms of
Incentive Stock Option Grant Agreements, Nonqualified Stock
Option Grant Agreements and Restricted Stock Grant Agreement
thereunder
|
|
10
|
.14
|
|
2010 Employee Stock Purchase Plan
|
|
10
|
.15
|
|
Employment Agreement between NuPathe Inc. and Jane H.
Hollingsworth
|
|
10
|
.16
|
|
Employment Agreement between NuPathe Inc. and Terri B. Sebree
|
|
10
|
.17
|
|
Employment Agreement between NuPathe Inc. and Keith A. Goldan
|
|
10
|
.18
|
|
Employment Agreement between NuPathe Inc. and Gerald W.
McLaughlin
|
|
10
|
.19
|
|
Employment Agreement between NuPathe Inc. and Ezra H. Felker
|
|
10
|
.20
|
|
Form of Indemnification Agreement
|
|
|
|
|
|
Exhibit
|
|
|
Number
|
|
Description of Document
|
|
|
10
|
.21
|
|
List of current directors with an Indemnification Agreement in
the form provided as Exhibit 10.20
|
|
23
|
.1
|
|
Consent of KPMG LLP, independent registered public accounting
firm
|
|
23
|
.2
|
|
Consent of Morgan, Lewis & Bockius LLP (included in
Exhibit 5.1)
|
|
24
|
.1
|
|
Power of Attorney (included in the signature page to this
registration statement)
|
|
24
|
.2
|
|
Power of Attorney for Wayne. P. Yetter
|
|
24
|
.3
|
|
Power of Attorney for Robert P. Roche, Jr.
|
|
|
|
|
|
Previously filed. |
|
# |
|
Confidential treatment requested under 17 C.F.R.
§§ 200.80(b)(4) and 230.406. The confidential
portions of this exhibit have been omitted and are marked
accordingly. The confidential portions have been filed
separately with the Securities and Exchange Commission. |